BRIVARACETAM
Information current as at: 1 September 2026
Submission Details
- Brand name:
-
- Briviact®
- Form and strength:
-
- Oral solution 10 mg per mL, 300 mL
- Submission sponsor:
- UCB AUSTRALIA PROPRIETARY LIMITED
- Condition/indication:
(therapeutic use) -
- Intractable focal onset seizures
- Listing requested:
- To request that brivaracetam oral liquid be considered as an exempt item under section 84AH of the National Health Act 1953. Where a pharmaceutical item is determined to be an exempt item, that pharmaceutical item is excluded from fifteen year Anniversary Price, first new brand and price disclosure reductions. Exempt items are not exempt from five and ten year Anniversary Price reductions.
- Funding program:
- PBS General Schedule
- Request authority level:
- Authority Required (STREAMLINED)
- PBAC Submission type:
- Change to existing listing (Category 4)
- Comment:
- --
- Other PBAC consideration:
- --
Progress Details
-
Submission received for: - July 2026 PBAC meeting
-
Opportunity for consumer comment: - Open 25/03/2026 and close 20/05/2026 (see PBS Website)
-
PBAC meeting: - Held on 08/07/2026
-
PBAC outcome published: - Advice Provided (see PBAC Outcomes)
-
5Lodgement of required documentation:
-
6Agreement to listing arrangements:
- Has not yet commenced
-
7Government processes:
- Has not yet commenced
-
8Medicine listed on the PBS:
- Has not yet occurred
PBAC Outcome
The PBAC advised the Minister, under subsection 101(4AB) of the National Health Act 1953, that brivaracetam oral solution, 10 mg per mL, 300 mg (Briviact®) met particular circumstances to be considered an exempt item under section 84AH of the Act. The PBAC considered that the oral solution form of brivaracetam was the only suitable PBS listed option for the treatment of intractable focal onset seizures for patients who cannot swallow tablets, or who require accurate weight-based dosing.
Case ID
1217
Page last updated
31 August 2026
v.9.19